

Gary J Nabel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7477406/publications.pdf>

Version: 2024-02-01

101
papers

19,639
citations

16437

64
h-index

30058

103
g-index

109
all docs

109
docs citations

109
times ranked

15130
citing authors

#	ARTICLE	IF	CITATIONS
1	Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1. <i>Science</i> , 2010, 329, 856-861.	6.0	1,600
2	Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01. <i>Science</i> , 2010, 329, 811-817.	6.0	1,050
3	Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. <i>Nature</i> , 2011, 480, 336-343.	13.7	794
4	Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing. <i>Science</i> , 2011, 333, 1593-1602.	6.0	788
5	HIV vaccine design and the neutralizing antibody problem. <i>Nature Immunology</i> , 2004, 5, 233-236.	7.0	721
6	HTLV-1 transactivator induces interleukin-2 receptor expression through an NF- κ B-like factor. <i>Nature</i> , 1988, 333, 776-778.	13.7	693
7	Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. <i>Nature</i> , 2013, 499, 102-106.	13.7	682
8	Activation of HIV gene expression during monocyte differentiation by induction of NF- κ B. <i>Nature</i> , 1989, 339, 70-73.	13.7	635
9	Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. <i>Nature Medicine</i> , 2015, 21, 1065-1070.	15.2	567
10	Cloning of an NF- κ B subunit which stimulates HIV transcription in synergy with p65. <i>Nature</i> , 1991, 352, 733-736.	13.7	446
11	A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. <i>Nature Medicine</i> , 2010, 16, 334-338.	15.2	403
12	Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors. <i>Journal of Virology</i> , 2011, 85, 9998-10009.	1.5	393
13	Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo. <i>Nature</i> , 1993, 362, 844-846.	13.7	382
14	Regulation of the Proinflammatory Effects of Fas Ligand (CD95L). , 1998, 282, 1714-1717.		339
15	Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies. <i>Immunity</i> , 2013, 39, 245-258.	6.6	332
16	Induction of Broadly Neutralizing H1N1 Influenza Antibodies by Vaccination. <i>Science</i> , 2010, 329, 1060-1064.	6.0	328
17	Epstein-Barr Virus: An Important Vaccine Target for Cancer Prevention. <i>Science Translational Medicine</i> , 2011, 3, 107fs7.	5.8	311
18	Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. <i>Nature</i> , 2014, 514, 642-645.	13.7	308

#	ARTICLE	IF	CITATIONS
19	Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. <i>Nature Reviews Immunology</i> , 2013, 13, 693-701.	10.6	302
20	Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. <i>Journal of Experimental Medicine</i> , 2014, 211, 2061-2074.	4.2	297
21	Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. <i>Journal of Experimental Medicine</i> , 2009, 206, 1117-1134.	4.2	295
22	Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site. <i>Cell</i> , 2015, 162, 1090-1100.	13.5	278
23	Structural basis for diverse N-glycan recognition by HIV-1 neutralizing V1V2 directed antibody PG16. <i>Nature Structural and Molecular Biology</i> , 2013, 20, 804-813.	3.6	257
24	Structural and genetic basis for development of broadly neutralizing influenza antibodies. <i>Nature</i> , 2012, 489, 566-570.	13.7	250
25	Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody <i>In Vitro</i> Improves Protection against Lentiviral Infection <i>In Vivo</i> . <i>Journal of Virology</i> , 2014, 88, 12669-12682.	1.5	248
26	Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection. <i>PLoS ONE</i> , 2014, 9, e87572.	1.1	248
27	Designing Tomorrow's Vaccines. <i>New England Journal of Medicine</i> , 2013, 368, 551-560.	13.9	237
28	Accelerating Next-Generation Vaccine Development for Global Disease Prevention. <i>Science</i> , 2013, 340, 1232910.	6.0	236
29	A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. <i>Vaccine</i> , 2008, 26, 6338-6343.	1.7	230
30	Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. <i>Science</i> , 2017, 358, 85-90.	6.0	225
31	Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. <i>Science Translational Medicine</i> , 2014, 6, 243ra88.	5.8	222
32	Flow Cytometry Reveals that H5N1 Vaccination Elicits Cross-Reactive Stem-Directed Antibodies from Multiple Ig Heavy-Chain Lineages. <i>Journal of Virology</i> , 2014, 88, 4047-4057.	1.5	220
33	Immunization by Avian H5 Influenza Hemagglutinin Mutants with Altered Receptor Binding Specificity. <i>Science</i> , 2007, 317, 825-828.	6.0	212
34	Immunization for Ebola virus infection. <i>Nature Medicine</i> , 1998, 4, 37-42.	15.2	211
35	Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. <i>Lancet</i> , 2014, 384, 2046-2052.	6.3	206
36	HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration. <i>Nature</i> , 2013, 498, 376-379.	13.7	203

#	ARTICLE	IF	CITATIONS
37	Cross-Neutralization of 1918 and 2009 Influenza Viruses: Role of Glycans in Viral Evolution and Vaccine Design. <i>Science Translational Medicine</i> , 2010, 2, 24ra21.	5.8	202
38	CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. <i>Nature Medicine</i> , 2011, 17, 1128-1131.	15.2	200
39	Next-generation influenza vaccines: opportunities and challenges. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 239-252.	21.5	192
40	DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 916-924.	4.6	174
41	Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. <i>Nature</i> , 2014, 505, 502-508.	13.7	140
42	Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation. <i>Nature Cancer</i> , 2020, 1, 86-98.	5.7	140
43	Comparative Efficacy of Neutralizing Antibodies Elicited by Recombinant Hemagglutinin Proteins from Avian H5N1 Influenza Virus. <i>Journal of Virology</i> , 2008, 82, 6200-6208.	1.5	139
44	Modifications of the Human Immunodeficiency Virus Envelope Glycoprotein Enhance Immunogenicity for Genetic Immunization. <i>Journal of Virology</i> , 2002, 76, 5357-5368.	1.5	137
45	Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. <i>Nature Medicine</i> , 2010, 16, 1389-1391.	15.2	136
46	Rational Design of Vaccines to Elicit Broadly Neutralizing Antibodies to HIV-1. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2011, 1, a007278-a007278.	2.9	135
47	Immunotherapy of Malignancy by In Vivo Gene Transfer into Tumors. <i>Human Gene Therapy</i> , 1992, 3, 399-410.	1.4	126
48	Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses. <i>PLoS ONE</i> , 2010, 5, e9015.	1.1	125
49	The Development of CD4 Binding Site Antibodies during HIV-1 Infection. <i>Journal of Virology</i> , 2012, 86, 7588-7595.	1.5	123
50	Prime-Boost Interval Matters: A Randomized Phase 1 Study to Identify the Minimum Interval Necessary to Observe the H5 DNA Influenza Vaccine Priming Effect. <i>Journal of Infectious Diseases</i> , 2013, 208, 418-422.	1.9	117
51	Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells. <i>Immunity</i> , 2019, 50, 1305-1316.e6.	6.6	107
52	Neutralizing Antibodies Elicited by Immunization of Monkeys with DNA Plasmids and Recombinant Adenoviral Vectors Expressing Human Immunodeficiency Virus Type 1 Proteins. <i>Journal of Virology</i> , 2005, 79, 771-779.	1.5	100
53	Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2015, 89, 8334-8345.	1.5	100
54	Comparative Analysis of the Magnitude, Quality, Phenotype, and Protective Capacity of Simian Immunodeficiency Virus Gag-Specific CD8+ T Cells following Human-, Simian-, and Chimpanzee-Derived Recombinant Adenoviral Vector Immunization. <i>Journal of Immunology</i> , 2013, 190, 2720-2735.	0.4	99

#	ARTICLE	IF	CITATIONS
55	Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2015, 89, 5895-5903.	1.5	92
56	Immunotherapy for Cancer by Direct Gene Transfer into Tumors. Howard Hughes Medical Institute Research Laboratories, Ann Arbor, Michigan. <i>Human Gene Therapy</i> , 1994, 5, 57-77.	1.4	90
57	Activation and lysis of human CD4 cells latently infected with HIV-1. <i>Nature Communications</i> , 2015, 6, 8447.	5.8	88
58	The inhibition of pro-apoptotic ICE-like proteases enhances HIV replication. <i>Nature Medicine</i> , 1997, 3, 333-337.	15.2	86
59	Antibodies VRC01 and 10E8 Neutralize HIV-1 with High Breadth and Potency Even with Ig-Framework Regions Substantially Reverted to Germline. <i>Journal of Immunology</i> , 2014, 192, 1100-1106.	0.4	86
60	Inhibition of the alloantibody response by CD95 ligand. <i>Nature Medicine</i> , 1997, 3, 843-848.	15.2	85
61	H5N1 Vaccine Elicited Memory B Cells Are Genetically Constrained by the IGHV Locus in the Recognition of a Neutralizing Epitope in the Hemagglutinin Stem. <i>Journal of Immunology</i> , 2015, 195, 602-610.	0.4	83
62	Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. <i>Science Translational Medicine</i> , 2021, 13, eabc7804.	5.8	79
63	The need and challenges for development of an Epstein-Barr virus vaccine. <i>Vaccine</i> , 2013, 31, B194-B196.	1.7	77
64	Protective immunity to lethal challenge of the 1918 pandemic influenza virus by vaccination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 15987-15991.	3.3	74
65	A Molecular Genetic Intervention for AIDS Effects of a Transdominant Negative Form of Rev. Hughes Medical Institute Research Laboratories, Ann Arbor, Michigan. <i>Human Gene Therapy</i> , 1994, 5, 79-92.	1.4	69
66	Mechanism of Ad5 Vaccine Immunity and Toxicity: Fiber Shaft Targeting of Dendritic Cells. <i>PLoS Pathogens</i> , 2007, 3, e25.	2.1	69
67	A respiratory syncytial virus (RSV) F protein nanoparticle vaccine focuses antibody responses to a conserved neutralization domain. <i>Science Immunology</i> , 2020, 5, .	5.6	67
68	A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells. <i>Nature</i> , 2022, 603, 328-334.	13.7	67
69	HIV-1 Vaccines and Adaptive Trial Designs. <i>Science Translational Medicine</i> , 2011, 3, 79ps13.	5.8	60
70	Differential Specificity and Immunogenicity of Adenovirus Type 5 Neutralizing Antibodies Elicited by Natural Infection or Immunization. <i>Journal of Virology</i> , 2010, 84, 630-638.	1.5	57
71	Elicitation of Broadly Neutralizing Influenza Antibodies in Animals with Previous Influenza Exposure. <i>Science Translational Medicine</i> , 2012, 4, 147ra114.	5.8	54
72	Progress in the rational design of an AIDS vaccine. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2011, 366, 2759-2765.	1.8	50

#	ARTICLE	IF	CITATIONS
73	Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	49
74	Systemic immune checkpoint blockade with anti-PD1 antibodies does not alter cerebral amyloid β burden in several amyloid transgenic mouse models. <i>Glia</i> , 2018, 66, 492-504.	2.5	46
75	Design of a broadly reactive Lyme disease vaccine. <i>Npj Vaccines</i> , 2020, 5, 33.	2.9	45
76	Enhanced Exposure of the CD4-Binding Site to Neutralizing Antibodies by Structural Design of a Membrane-Anchored Human Immunodeficiency Virus Type 1 gp120 Domain. <i>Journal of Virology</i> , 2009, 83, 5077-5086.	1.5	43
77	A virus-like particle vaccine prevents equine encephalitis virus infection in nonhuman primates. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	42
78	Development of a Pan-H1 Influenza Vaccine. <i>Journal of Virology</i> , 2018, 92, .	1.5	39
79	Outer Domain of HIV-1 gp120: Antigenic Optimization, Structural Malleability, and Crystal Structure with Antibody VRC-PG04. <i>Journal of Virology</i> , 2013, 87, 2294-2306.	1.5	34
80	Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. <i>Nature Medicine</i> , 2022, 28, 1022-1030.	15.2	34
81	A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice. <i>Science Translational Medicine</i> , 2022, 14, eabf3685.	5.8	34
82	Gene-Based Vaccination with a Mismatched Envelope Protects against Simian Immunodeficiency Virus Infection in Nonhuman Primates. <i>Journal of Virology</i> , 2012, 86, 7760-7770.	1.5	31
83	Enhanced Induction of Intestinal Cellular Immunity by Oral Priming with Enteric Adenovirus 41 Vectors. <i>Journal of Virology</i> , 2009, 83, 748-756.	1.5	25
84	Tampering with transcription. <i>Nature</i> , 1991, 350, 658-658.	13.7	24
85	Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination. <i>PLoS ONE</i> , 2012, 7, e33969.	1.1	22
86	Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults. <i>PLoS ONE</i> , 2015, 10, e0123969.	1.1	22
87	Direct Gene Transfer for the Understanding and Treatment of Human Disease. <i>Annals of the New York Academy of Sciences</i> , 1994, 716, 144-153.	1.8	21
88	Potent anti-viral activity of a trispesific HIV neutralizing antibody in SHIV-infected monkeys. <i>Cell Reports</i> , 2022, 38, 110199.	2.9	19
89	Combination recombinant simian or chimpanzee adenoviral vectors for vaccine development. <i>Vaccine</i> , 2015, 33, 7344-7351.	1.7	16
90	Comparison of adjuvants to optimize influenza neutralizing antibody responses. <i>Vaccine</i> , 2019, 37, 6208-6220.	1.7	16

#	ARTICLE	IF	CITATIONS
91	Gene delivery of a modified antibody to A β reduces progression of murine Alzheimer's disease. PLoS ONE, 2019, 14, e0226245.	1.1	16
92	Patents, economics, and pandemics. Science, 2020, 368, 1035-1035.	6.0	13
93	Extrachromosomal human immunodeficiency virus type-1 DNA can initiate a spreading infection of HL-60 cells. Journal of Cellular Biochemistry, 1991, 45, 366-373.	1.2	12
94	Comparative Immunogenicity of Human Immunodeficiency Virus Particles and Corresponding Polypeptides in a DNA Vaccine. Journal of Virology, 2005, 79, 626-631.	1.5	8
95	HIV integration and T cell death: additional commentary. Retrovirology, 2013, 10, 150.	0.9	6
96	Immunogenicity and protective efficacy of RSV G central conserved domain vaccine with a prefusion nanoparticle. Npj Vaccines, 2022, 7, .	2.9	6
97	Liposome Mediated Gene Transfer into Vascular Cells. Journal of Liposome Research, 1993, 3, 179-199.	1.5	5
98	Calories lost " another mediator of cancer cachexia?. Nature Medicine, 1996, 2, 397-398.	15.2	5
99	All for one and one for all to fight flu. Nature, 2019, 565, 29-31.	13.7	3
100	Report of the Cent Gardes HIV Vaccines Conference. Part 1: The antibody response; Fondation M $\text{\r{e}}$ rioux Conference Center, Veyrier-du-Lac, France, 25-27 October 2015. Vaccine, 2016, 34, 3557-3561.	1.7	2
101	Development of Molecular Genetic Interventions for HIV Infection. Current Protocols in Human Genetics, 1997, 12, Unit 13.6.	3.5	0